Literature DB >> 29558126

Synthesis and Evaluation of the First Fluorescent Antagonists of the Human P2Y2 Receptor Based on AR-C118925.

Sean Conroy1, Nicholas D Kindon1, Jacqueline Glenn2,3, Leigh A Stoddart2,3, Richard J Lewis4, Stephen J Hill2,3, Barrie Kellam1,3, Michael J Stocks1.   

Abstract

The human P2Y2 receptor ( hP2Y2R) is a G-protein-coupled receptor that shows promise as a therapeutic target for many important conditions, including for antimetastatic cancer and more recently for idiopathic pulmonary fibrosis. As such, there is a need for new hP2Y2R antagonists and molecular probes to study this receptor. Herein, we report the development of a new series of non-nucleotide hP2Y2R antagonists, based on the known, non-nucleotide hP2Y2R antagonist AR-C118925 (1), leading to the discovery of a series of fluorescent ligands containing different linkers and fluorophores. One of these conjugates, 98, displayed micromolar affinity for hP2Y2R (p Kd = 6.32 ± 0.10, n = 17) in a bioluminescence-energy-transfer (BRET) assay. Confocal microscopy with this ligand revealed displaceable membrane labeling of astrocytoma cells expressing untagged hP2Y2R. These properties make 98 one of the first tools for studying hP2Y2R distribution and organization.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29558126      PMCID: PMC6026847          DOI: 10.1021/acs.jmedchem.8b00139

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  25 in total

1.  Arylpiperazine substituted heterocycles as selective alpha(1a) adrenergic antagonists.

Authors:  Haripada Khatuya; Richard H Hutchings; Gee-Hong Kuo; Virginia L Pulito; Linda K Jolliffe; Xiaobing Li; William V Murray
Journal:  Bioorg Med Chem Lett       Date:  2002-09-02       Impact factor: 2.823

2.  Assessment of additive/nonadditive effects in structure-activity relationships: implications for iterative drug design.

Authors:  Yogendra Patel; Valerie J Gillet; Trevor Howe; Joaquin Pastor; Julen Oyarzabal; Peter Willett
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

3.  Conversion of a non-selective adenosine receptor antagonist into A3-selective high affinity fluorescent probes using peptide-based linkers.

Authors:  Andrea J Vernall; Leigh A Stoddart; Stephen J Briddon; Hui Wen Ng; Charles A Laughton; Stephen W Doughty; Stephen J Hill; Barrie Kellam
Journal:  Org Biomol Chem       Date:  2013-09-14       Impact factor: 3.876

4.  NanoBRET--A Novel BRET Platform for the Analysis of Protein-Protein Interactions.

Authors:  Thomas Machleidt; Carolyn C Woodroofe; Marie K Schwinn; Jacqui Méndez; Matthew B Robers; Kris Zimmerman; Paul Otto; Danette L Daniels; Thomas A Kirkland; Keith V Wood
Journal:  ACS Chem Biol       Date:  2015-06-09       Impact factor: 5.100

Review 5.  Drug-like Antagonists of P2Y Receptors-From Lead Identification to Drug Development.

Authors:  Sean Conroy; Nicholas Kindon; Barrie Kellam; Michael J Stocks
Journal:  J Med Chem       Date:  2016-08-01       Impact factor: 7.446

6.  Development and Characterization of a Fluorescent Tracer for the Free Fatty Acid Receptor 2 (FFA2/GPR43).

Authors:  Anders Højgaard Hansen; Eugenia Sergeev; Sunil K Pandey; Brian D Hudson; Elisabeth Christiansen; Graeme Milligan; Trond Ulven
Journal:  J Med Chem       Date:  2017-06-16       Impact factor: 7.446

7.  Structural determination of molecular stereochemistry using VCD spectroscopy and a conformational code: absolute configuration and solution conformation of a chiral liquid pesticide, (R)-(+)-malathion.

Authors:  Hiroshi Izumi; Atsushi Ogata; Laurence A Nafie; Rina K Dukor
Journal:  Chirality       Date:  2009       Impact factor: 2.437

8.  Application of BRET to monitor ligand binding to GPCRs.

Authors:  Stephen J Hill; Kevin D G Pfleger; Leigh A Stoddart; Elizabeth K M Johnstone; Amanda J Wheal; Joëlle Goulding; Matthew B Robers; Thomas Machleidt; Keith V Wood
Journal:  Nat Methods       Date:  2015-06-01       Impact factor: 28.547

9.  Illuminating the life of GPCRs.

Authors:  Ilka Böhme; Annette G Beck-Sickinger
Journal:  Cell Commun Signal       Date:  2009-07-14       Impact factor: 5.712

10.  Development of selective agonists and antagonists of P2Y receptors.

Authors:  Kenneth A Jacobson; Andrei A Ivanov; Sonia de Castro; T Kendall Harden; Hyojin Ko
Journal:  Purinergic Signal       Date:  2008-07-04       Impact factor: 3.765

View more
  4 in total

Review 1.  Fluorescent ligands: Bringing light to emerging GPCR paradigms.

Authors:  Mark Soave; Stephen J Briddon; Stephen J Hill; Leigh A Stoddart
Journal:  Br J Pharmacol       Date:  2020-02-06       Impact factor: 8.739

2.  Optimization of Peptide Linker-Based Fluorescent Ligands for the Histamine H1 Receptor.

Authors:  Zhi Yuan Kok; Leigh A Stoddart; Sarah J Mistry; Tamara A M Mocking; Henry F Vischer; Rob Leurs; Stephen J Hill; Shailesh N Mistry; Barrie Kellam
Journal:  J Med Chem       Date:  2022-06-03       Impact factor: 8.039

Review 3.  Therapeutic potential for P2Y2 receptor antagonism.

Authors:  Kimberly J Jasmer; Kevin Muñoz Forti; Lucas T Woods; Seunghee Cha; Gary A Weisman
Journal:  Purinergic Signal       Date:  2022-10-11       Impact factor: 3.950

4.  Subtype selective fluorescent ligands based on ICI 118,551 to study the human β2-adrenoceptor in CRISPR/Cas9 genome-edited HEK293T cells at low expression levels.

Authors:  Joëlle Goulding; Sarah J Mistry; Mark Soave; Jeanette Woolard; Stephen J Briddon; Carl W White; Barrie Kellam; Stephen J Hill
Journal:  Pharmacol Res Perspect       Date:  2021-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.